News
DGAP-Adhoc: MorphoSys AG: Ad hoc: Primary Endpoint met in Real-World Data Study Demonstrating Clinical Superiority of the Combination of Tafasitamab and Lenalidomide compared to Lenalidomide alone
DGAP-Adhoc: MorphoSys AG: Ad hoc: Primary Endpoint met in Real-World Data Study Demonstrating Clinical Superiority of the Combination of Tafasitamab and Lenalidomide compared to Lenalidomide alone
![Form 8.3 - The Vanguard Group, Inc.: AbbVie plc](/assets/news/news6-ad07925a95156ae03dbe17caf44a9dc29f254ff2c2a42c7678d35288ad55cec8.png)
Form 8.3 - The Vanguard Group, Inc.: AbbVie plc
Form 8.3 - The Vanguard Group, Inc.: AbbVie plc
![DGAP-News: MPH Health Care AG: Vorläufiges IFRS-Ergebnis drittes Quartal 2019: NAV je Aktie mit 5,60 Euro weiterhin deutlich über aktuellem Kursniveau](/assets/news/news11-1ebbf8540812dc8f080ecfeb67ce19c492651a7c439bd800cec2630c3a04a840.png)
DGAP-News: MPH Health Care AG: Vorläufiges IFRS-Ergebnis drittes Quartal 2019: NAV je Aktie mit 5,60 Euro weiterhin deutlich über aktuellem Kursniveau
DGAP-News: MPH Health Care AG: Vorläufiges IFRS-Ergebnis drittes Quartal 2019: NAV je Aktie mit 5,60 Euro weiterhin deutlich über aktuellem Kursniveau
![DGAP-News: MPH Health Care AG: Preliminary IFRS result for third quarter of 2019: NAV per share at EUR 5.60 still well above current stock level](/assets/news/news12-a6c8e663da6f66e4f8b76885d84b91bc276bfd92fd8727e9ade1f1d9f4df9b67.png)
DGAP-News: MPH Health Care AG: Preliminary IFRS result for third quarter of 2019: NAV per share at EUR 5.60 still well above current stock level
DGAP-News: MPH Health Care AG: Preliminary IFRS result for third quarter of 2019: NAV per share at EUR 5.60 still well above current stock level
DGAP-News: Biotest AG: Biotest zeigt exzellente Wirksamkeit und Verträglichkeit von Haemoctin(R) SDH in Langzeitstudie bei Patienten mit Hämophilie A
DGAP-News: Biotest AG: Biotest zeigt exzellente Wirksamkeit und Verträglichkeit von Haemoctin(R) SDH in Langzeitstudie bei Patienten mit Hämophilie A
DGAP-News: Biotest AG: Biotest shows excellent efficacy and tolerability of Haemoctin(R) SDH in long-term study of patients with haemophilia A
DGAP-News: Biotest AG: Biotest shows excellent efficacy and tolerability of Haemoctin(R) SDH in long-term study of patients with haemophilia A
DGAP-News: MorphoSys AG: Klinische Entwicklung von MOR106 in atopischer Dermatitis aufgrund Ergebnis von nutzenbasierter Zwischenanalyse gestoppt
DGAP-News: MorphoSys AG: Klinische Entwicklung von MOR106 in atopischer Dermatitis aufgrund Ergebnis von nutzenbasierter Zwischenanalyse gestoppt
DGAP-News: MorphoSys AG: MOR106 Clinical Development in Atopic Dermatitis Stopped
DGAP-News: MorphoSys AG: MOR106 Clinical Development in Atopic Dermatitis Stopped
DGAP-Adhoc: MorphoSys AG: Ad hoc: Klinische Entwicklung von MOR106 in atopischer Dermatitis aufgrund Ergebnis von nutzenbasierter Zwischenanalyse gestoppt
DGAP-Adhoc: MorphoSys AG: Ad hoc: Klinische Entwicklung von MOR106 in atopischer Dermatitis aufgrund Ergebnis von nutzenbasierter Zwischenanalyse gestoppt
DGAP-Adhoc: MorphoSys AG: Ad hoc: MOR106 Clinical Development in Atopic Dermatitis Stopped for Futility
DGAP-Adhoc: MorphoSys AG: Ad hoc: MOR106 Clinical Development in Atopic Dermatitis Stopped for Futility
![Form 8.3 - The Vanguard Group, Inc.: AbbVie plc](/assets/news/news6-ad07925a95156ae03dbe17caf44a9dc29f254ff2c2a42c7678d35288ad55cec8.png)
Form 8.3 - The Vanguard Group, Inc.: AbbVie plc
Form 8.3 - The Vanguard Group, Inc.: AbbVie plc
![Hardman & Co Research: genedrive plc (GDR): Acceleration of news flow expected](/assets/news/news3-3816cd3656012f9a06bae00ff06108b383643da017a8247fff474f84ea8a7c5a.png)
Hardman & Co Research: genedrive plc (GDR): Acceleration of news flow expected
Hardman & Co Research: genedrive plc (GDR): Acceleration of news flow expected
![DGAP-News: Formycon AG: Formycon gibt Start der klinischen Phase I Studie mit Ustekinumab-Biosimilar-Kandidat FYB202 bekannt](/assets/news/news16-82a218458f0e15ae617f9186b258dfd3add112716106c6ee3cbb48563ccdef52.png)
DGAP-News: Formycon AG: Formycon gibt Start der klinischen Phase I Studie mit Ustekinumab-Biosimilar-Kandidat FYB202 bekannt
DGAP-News: Formycon AG: Formycon gibt Start der klinischen Phase I Studie mit Ustekinumab-Biosimilar-Kandidat FYB202 bekannt
![DGAP-News: Formycon AG: Formycon announces Start of Phase I Clinical Trial with Ustekinumab Biosimilar Candidate FYB202](/assets/news/news18-f135f6c168ef56d2b112890081403b0a310104acfadbf4a8f72634bd390e98ac.png)
DGAP-News: Formycon AG: Formycon announces Start of Phase I Clinical Trial with Ustekinumab Biosimilar Candidate FYB202
DGAP-News: Formycon AG: Formycon announces Start of Phase I Clinical Trial with Ustekinumab Biosimilar Candidate FYB202
![Form 8.3 - The Vanguard Group, Inc.: AbbVie plc](/assets/news/news10-be520e400538f920c1970757e43cd0aa35625c1095be243829bb7a152346bd95.png)
Form 8.3 - The Vanguard Group, Inc.: AbbVie plc
Form 8.3 - The Vanguard Group, Inc.: AbbVie plc
![DGAP-News: Heidelberg Pharma AG: Pflichtwandlungsmitteilung](/assets/news/news4-fce0efe65d8ba787508ef718c0a20bed51e468dbc656c188c43e13f15b4a4f53.png)
DGAP-News: Heidelberg Pharma AG: Pflichtwandlungsmitteilung
DGAP-News: Heidelberg Pharma AG: Pflichtwandlungsmitteilung
![DGAP-News: Heidelberg Pharma AG: Notice to Holders](/assets/news/news5-af8c677c86bb4b693f58afef33877e6f798ff0d7e2b4fa69b6e89960549b5ee6.png)
DGAP-News: Heidelberg Pharma AG: Notice to Holders
DGAP-News: Heidelberg Pharma AG: Notice to Holders
![Form 8.3 - The Vanguard Group, Inc.: AbbVie plc](/assets/news/news12-a6c8e663da6f66e4f8b76885d84b91bc276bfd92fd8727e9ade1f1d9f4df9b67.png)
Form 8.3 - The Vanguard Group, Inc.: AbbVie plc
Form 8.3 - The Vanguard Group, Inc.: AbbVie plc
![DGAP-News: Vivoryon Therapeutics AG: NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA, CANADA, AUSTRALIA OR JAPAN OR ANY OTHER JURISDICTION IN WHICH THE RELEASE WOULD BE UNLAWFUL.](/assets/news/news14-e52b56a6adda780de8ab40d75cabe14dcfa77fc9676e986401297a29e68c991e.png)
DGAP-News: Vivoryon Therapeutics AG: NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA, CANADA, AUSTRALIA OR JAPAN OR ANY OTHER JURISDICTION IN WHICH THE RELEASE WOULD BE UNLAWFUL.
DGAP-News: Vivoryon Therapeutics AG: NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA, CANADA, AUSTRALIA OR JAPAN OR ANY OTHER JURISDICTION IN WHICH THE RELEASE WOULD BE UNLAWFUL.
![Form 8.3 - The Vanguard Group, Inc.: AbbVie plc](/assets/news/news13-125fa69a38b6955d740c18f7e750c42a3317f6873eded3044187d2ece3aa0ac7.png)
Form 8.3 - The Vanguard Group, Inc.: AbbVie plc
Form 8.3 - The Vanguard Group, Inc.: AbbVie plc
![DGAP-News: Biofrontera AG: Biofrontera Receives Award at Fall Clinical Dermatology Conference 2019](/assets/news/news8-29d1d55c755b03e328399113b5bdd004223f995e95194ba5ee80af9da39a41e3.png)
DGAP-News: Biofrontera AG: Biofrontera Receives Award at Fall Clinical Dermatology Conference 2019
DGAP-News: Biofrontera AG: Biofrontera Receives Award at Fall Clinical Dermatology Conference 2019
![DGAP-News: Biofrontera AG: Biofrontera erhält Auszeichnung bei Fall Clinical Dermatology Conference 2019](/assets/news/news4-fce0efe65d8ba787508ef718c0a20bed51e468dbc656c188c43e13f15b4a4f53.png)
DGAP-News: Biofrontera AG: Biofrontera erhält Auszeichnung bei Fall Clinical Dermatology Conference 2019
DGAP-News: Biofrontera AG: Biofrontera erhält Auszeichnung bei Fall Clinical Dermatology Conference 2019
![DGAP-News: EVOTEC, INTEGRA HOLDINGS UND YISSUM STARTEN LAB555, UM FRÜHE WIRKSTOFFENTWICKLUNG ZU BESCHLEUNIGEN: http://s3-eu-west-1.amazonaws.com/sharewise-dev/attachment/file/23749/Evotec_high_res_logo_%28blue_and_grey%29.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBMUT09IiwiZXhwIjpudWxsLCJwdXIiOiJibG9iX2lkIn19--5ccaaee20e4dd47dccd2b888e74ce998199f16f5/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/Evotec_high_res_logo_-28blue_and_grey-29.jpg?locale=us)
DGAP-News: EVOTEC, INTEGRA HOLDINGS UND YISSUM STARTEN LAB555, UM FRÜHE WIRKSTOFFENTWICKLUNG ZU BESCHLEUNIGEN
DGAP-News: EVOTEC, INTEGRA HOLDINGS UND YISSUM STARTEN LAB555, UM FRÜHE WIRKSTOFFENTWICKLUNG ZU BESCHLEUNIGEN
![DGAP-News: EVOTEC, INTEGRA HOLDINGS AND YISSUM ESTABLISH LAB555 TO FAST TRACK EARLY-STAGE DRUG DEVELOPMENT: http://s3-eu-west-1.amazonaws.com/sharewise-dev/attachment/file/23749/Evotec_high_res_logo_%28blue_and_grey%29.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBMUT09IiwiZXhwIjpudWxsLCJwdXIiOiJibG9iX2lkIn19--5ccaaee20e4dd47dccd2b888e74ce998199f16f5/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/Evotec_high_res_logo_-28blue_and_grey-29.jpg?locale=us)
DGAP-News: EVOTEC, INTEGRA HOLDINGS AND YISSUM ESTABLISH LAB555 TO FAST TRACK EARLY-STAGE DRUG DEVELOPMENT
DGAP-News: EVOTEC, INTEGRA HOLDINGS AND YISSUM ESTABLISH LAB555 TO FAST TRACK EARLY-STAGE DRUG DEVELOPMENT
![Form 8.3 - The Vanguard Group, Inc.: AbbVie plc](/assets/news/news12-a6c8e663da6f66e4f8b76885d84b91bc276bfd92fd8727e9ade1f1d9f4df9b67.png)
Form 8.3 - The Vanguard Group, Inc.: AbbVie plc
Form 8.3 - The Vanguard Group, Inc.: AbbVie plc